Cell therapy (Stem-cell derived) · developed by Mesoblast
Mesenchymal Precursor Cells (MPC) are cells given by single intravenous infusion, in doses of 12.5 M or 25 M.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01781390 | Phase 2 | Acute Myocardial Infarction | Completed | MESO |
| NCT01576328 | Phase 1/2 | Type 2 Diabetes | Completed | MESO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myocardial InfarctionType 2 Diabetes
Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.
See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MESO catalysts and pipeline →